Vir Biotechnology Newsroom

Vir Biotechnology Analyst Ratings

BenzingaApr 17 13:52 ET

Goldman Sachs Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $21

Moomoo NewsApr 16 11:31 ET

Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsMar 14 11:32 ET

Vir Biotechnology's Strategic Advancements and Financial Health Justify Buy Rating

TipRanksMar 3 02:01 ET

Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $31

Moomoo NewsMar 1 07:32 ET

Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $31

BenzingaFeb 28 16:55 ET

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow JonesFeb 28 09:57 ET

Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsFeb 27 08:35 ET

Vir Biotechnology Analyst Ratings

BenzingaFeb 27 08:04 ET

A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $14 to $20

Moomoo NewsFeb 27 08:02 ET

Vir Biotechnology: Balancing Long-term Potential With Near-term Uncertainty – A Hold Rating Analysis

TipRanksFeb 27 06:42 ET

Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsFeb 13 07:33 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Irhythm Technologies (IRTC), Vir Biotechnology (VIR) and Biogen (BIIB)

TipRanksFeb 13 06:41 ET

BofA Securities Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $14

Moomoo NewsJan 15 05:33 ET

Bank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)

TipRanksJan 15 05:18 ET

Vir Biotechnology Is Maintained at Outperform by Leerink Partners

Dow JonesJan 13 11:29 ET

Vir Biotechnology Analyst Ratings

BenzingaJan 13 11:20 ET

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)

TipRanksJan 12 07:41 ET

Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsJan 10 09:31 ET

Morgan Stanley Upgrades Vir Biotechnology(VIR.US) to Buy Rating, Raises Target Price to $20

Moomoo NewsJan 10 06:35 ET